Loading
II
Icosavax, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by MCDADE MARK, was filed 05 Apr 2022.
Icosavax, Inc.: what insiders have been doing
This page follows insider dealings at Icosavax, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Icosavax, Inc. The previous disclosure was published on 20 February 2024.
Looking back to 2021, when coverage begins, insiders filed 15 purchases and 51 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
167
Thresholds
n/a
Buy Volume
€42M
15 ops. · all time
Sell Volume
€7M
51 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$79M
Last declaration on 20 February 2024
Declarations167 total
5,324,897 sharesCommon StockSEC:0001415889-24-004509:1
638,668 sharesCommon StockSEC:0001415889-24-004509:2
2,834 sharesCommon StockSEC:0000950170-24-017423:1
3,510,228 sharesCommon StockSEC:0000950170-24-017405:1
2,833 sharesCommon StockSEC:0000950170-24-017407:1
7,392 sharesCommon StockSEC:0000950170-24-017412:1
2,917 sharesCommon StockSEC:0000950170-24-017415:1
525,044 sharesCommon StockSEC:0000950170-24-017431:1
129,032 sharesCommon StockSEC:0000950170-24-017431:2
129,032 sharesCommon StockSEC:0000950170-24-017431:3
11,209 sharesCommon StockSEC:0000950170-24-017423:0
358,657 sharesCommon StockSEC:0000950170-24-017431:0
3,695 sharesCommon StockSEC:0000950170-24-017412:0
39,367 sharesCommon StockSEC:0000950170-24-017410:0
131,799 sharesCommon StockSEC:0000950170-24-017419:0
8,066 sharesCommon StockSEC:0000950170-24-017407:0
55,786 sharesCommon StockSEC:0000950170-24-017405:0
5,543 sharesCommon StockSEC:0001415889-24-004509:0
223,980 sharesCommon StockSEC:0000950170-24-017399:0
11,376 sharesCommon StockSEC:0000950170-24-017415:0
15,000 shares@ US$1.040.3% of flowCommon StockSEC:0000950170-24-010798:1
15,000 shares@ US$15.293.9% of flowCommon StockSEC:0000950170-24-010798:2
6,532 shares0Common StockSEC:0000950170-24-010798:0
93,227 shares@ US$1.041.6% of flowCommon StockSEC:0001209191-24-002106:1
4,789 shares@ US$0.840.1% of flowCommon StockSEC:0001209191-24-002106:0
25 of 167 declarations
About Icosavax, Inc.
Icosavax, Inc. (ticker: ICVX) was a U.S.-listed biopharmaceutical company on the NASDAQ market before its acquisition was completed in February 2024. For French-speaking investors in France, Belgium, or Switzerland, the core takeaway is that Icosavax operated in healthcare, specifically in next-generation vaccines, using a proprietary protein virus-like particle (VLP) platform. The company was based in the United States, with headquarters in Seattle, Washington, and it fit the profile of a U.S. clinical-stage biotech: research-intensive, capital-hungry, and focused on value creation through pipeline advancement rather than current product sales.
Founded in 2017, Icosavax was built around the goal of developing differentiated vaccines that could generate stronger immune responses than conventional approaches. Its lead asset was a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), aimed primarily at older adults, a population with significant unmet medical need and attractive long-term commercial potential. The company also pursued complementary respiratory disease programs, leveraging its VLP-based technology platform to create potentially broad vaccine applications.
Read moreShow less
From a competitive standpoint, Icosavax was a small-cap, clinical-stage player operating in a crowded and strategically important vaccine landscape. It competed indirectly with large pharmaceutical groups, specialist vaccine developers, and other platform-based biotech companies. Because it had not yet reached commercialization, its market position depended less on revenue generation and more on clinical differentiation, manufacturing feasibility, and the ability to prove that its technology could address meaningful respiratory disease targets. That profile made the company a typical high-risk, high-upside biotech investment.
The major recent event that defines the equity story is the acquisition by AstraZeneca, announced and completed in February 2024. This transaction validated the strategic value of the pipeline and the platform, and it effectively removed Icosavax as an independent listed company. As a result, any SEC Form 4 insider-transaction interest today is best viewed through an archival and transaction-history lens rather than as an ongoing standalone public equity story.
In practical terms, Icosavax is best described as an innovative U.S. vaccine biotech that was listed on NASDAQ in the United States, focused on respiratory vaccines and a proprietary VLP platform, and ultimately absorbed through M&A before reaching the commercial stage. Its history highlights the typical biotech investment arc: promising science, clinical-stage optionality, strategic interest from a larger pharmaceutical acquirer, and eventual exit via takeover rather than standalone scale-up.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
